Keytruda Lung Cancer Treatment

Posted on

Keytruda Lung Cancer Treatment

Keytruda Lung Cancer Treatment Canadian patients with non-metastatic small cell lung cancer (NSCLC) can now receive Merck’s Keytruda (pembrolizumab) as the first treatment following recent approval by health authorities. The homologation covers patients with tumors with high DP-L1 content, no tumor mutations in EGFR or ALK genes, and no previous chemotherapy treatment.

Keytruda Lung Cancer Treatment, keytruda lung cancer cost, keytruda lung cancer side effects, keytruda lung cancer life expectancy, keytruda lung cancer pbs, keytruda lung cancer survival, keytruda lung cancer trials,

“Lung cancer is the leading cause of cancer death in men and women in Canada, making this new indication particularly important.” We look forward to working with provinces and other jurisdictions to ensure Canadians who need immunotherapy for the first metastatic NSLC series have rapid access to Keytruda, “said Chirfi Goldberg, President and Chief Executive Officer of Merck Canada Canada and Canada.

In this type of lung cancer, higher DP-L1 levels have been associated with a better response to Keytruda treatment, and physicians can use a validated assay to determine the DP-L1 content in a tumor.

“NSCLC is an aggressive disease that can affect Canadians with lungs,” said Rosalyn Juergens, a medical oncologist at the Juravinski Cancer Center in Hamilton, Ontario.

Keytruda Lung Cancer Treatment we believe speed and good diagnostic tools, such as the DP-L1 bioassay test, are critical to the treatment of fatal diseases such as lung cancer. The key is to provide the right treatment as soon as possible to patients most likely to benefit. For patients with lung cancer, it is important to avoid wasting time in treatments that may not work for them, he added.

Approval was based on data from Key Phase 3 Clinical Trials (NCT02142738), which compared Keytruda as the only treatment for platinum chemotherapy, now the standard for metastatic NSCLC.

Keytruda Lung Cancer Treatment

Since the results showed that Keytruda lowered the risk of progression or death by 50%, and the risk of death by 40% compared to chemotherapy, the test was interrupted at an intermediate analysis in 2016 to allow patients in the control group to Receive Keytruda.

“At Lung Cancer Canada, we see every day how the shocks of lung cancer overwhelm and separates families,” said Shem Singh, executive director of Lung Cancer Canada.

“Patients need treatment options as part of the first line that works and allows them to spend quality time with their families.” Keytruda offers this potential to patients who meet the criteria. For this patient population, every moment counts, “added Singh.